12:00 PM EDT, 08/22/2024 (MT Newswires) -- Cadrenal Therapeutics ( CVKD ) said Thursday it is scheduled to have a type-B meeting with the US Food and Drug Administration in early September to discuss clinical trial for its tecarfarin treatment in left ventricular assist device, or LVAD, patients.

The company is developing tecarfarin to help prevent heart attacks, strokes and other cardiac issues.

LVADs are mechanical pumps to support heart function in patients with advanced heart failure.

Price: 7.27, Change: +0.02, Percent Change: +0.28